Table 1 Characteristics of all patients included in the present study.
Total | DA, IDH-wt | AA, IDH-wt | p-value* | |
|---|---|---|---|---|
All tumours | ||||
Number, n | 42 | 18 | 24 | |
Sex, men, n | 31 | 13 | 18 | 1 |
Age (year), median (range) | 55.5 (5–85) | 56.5 (5–85) | 55 (8–85) | 0.964 |
cIMPACT-NOW update 3 "grade 4", n | 21 | 9 | 12 | 1 |
TERTp mutation, n | 18 | 9 | 9 | 0.533 |
EGFR amplification, n | 8 | 1 | 7 | 0.109 |
EGFR gain and PTEN loss, n | 6 | 3 | 3 | 1 |
PTEN loss, n | 11 | 3 | 8 | 0.299 |
PDGFR amplification, n | 4 | 0 | 4 | 0.122 |
CDKN2A homozygous loss, n | 8 | 1 | 7 | 0.109 |
MGMTp hypermethylation, n | 13 | 6 | 7 | 1 |
Patients for survival analysis | ||||
Number, n | 40 | 18 | 22 | |
Age (years), median (range) | 57 (5–85) | 56.5 (5–85) | 59 (8–85) | 0.725 |
Initial treatment | ||||
Chemoradiotherapy, n | 28 | 9 | 19 | 0.0246 |
Chemotherapy, n | 2 | 1 | 1 | |
Observation, n | 10 | 8 | 2 | |
